ArticleJournal of the American Veterinary Medical Association2026
Dogs with sudden acquired retinal degeneration syndrome have evidence of a hypercoagulable state and decreased clot turnover.
Article in Journal of the American Veterinary Medical Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Objective: To evaluate plasma from dogs with sudden acquired retinal degeneration syndrome (SARDS) for coagulability, extent of clot turnover, and plasminogen activator inhibitor-1 (PAI-1) concentrations. Methods: Archived (2016 to 2017) or fresh (2023 to 2024) citrated plasma was collected (jugular venipuncture) at a university clinic from dogs with confirmed SARDS and controls (age, breed, and sex matched to a dog with SARDS). Light absorbance fibrinolysis assay assessed clot formation (clot formation velocity, peak optical density [POD], and area under the curve [AUC]) and degradation (percent clot lysis at 30 to 60 minutes, clot lysis velocity). Concentrations of PAI-1 were measured (ELISA). Results were analyzed with the Wilcoxon signed rank test, Spearman correlation, and multiple logistic regression. Results: There were 6 dogs with confirmed SARDS in the pilot study and 10 in the prospective study. Dogs with SARDS had higher POD and AUC than controls (POD median difference [MD] = 306 milliabsorbance units [mAU; pilot], 356 mAU [prospective]; AUC MD = 1,900 AU [pilot], 6,775 AU [prospective]), indicating greater extent of clot formation. Dogs with acute SARDS (< 6 months' duration; n = 11) had higher POD (MD = 382 mAU), AUC (MD = 4,857 AU), and clot formation velocity (MD = 0.6 mAU/s), indicating greater strength and rate of clot formation. Dogs with acute SARDS also had lower clot lysis at 30 minutes (MD = -16%) and 60 minutes (MD = -22%), indicating reduced clot lysis. The combined fibrinolysis assay outcomes allowed excellent differentiation between dogs with SARDS and controls (area under the receiver operating curve, 0.93). There was no difference in PAI-1 plasma concentrations between groups. Conclusions: Dogs with SARDS are hypercoagulable with evidence of decreased clot turnover in the acute stage. Clinical Relevance: Dogs with SARDS are hypercoagulable; reduced clot lysis may contribute to thrombus-associated ischemic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.